TABLE 2.
In vitro activity of VX-787 against influenza virus type A strains that are susceptible or resistant to oseltamivir carboxylate or amantadine
| Virus | Type/subtype | Phenotype |
Mean VX-787 EC50 (nM), no. of exptsc | |
|---|---|---|---|---|
| Oseltamivir carboxylatea | Amantadineb | |||
| A/WS/33 | A/H1N1 | S | R | 3.2 ± 4.3, n = 4 |
| A/Hong Kong/8/68 | A/H3N2 | S | S | 0.60 ± 0.11, n = 3 |
| A/Victoria/3/75 | A/H3N2 | S | S | 1.3 ± 0.63, n = 5 |
| A/Georgia/17/2006 | A/H1N1 | S | S | 0.13 ± 0.048, n = 3 |
| A/Georgia/20/2006 | A/H1N1 | R | S | 2.6 ± 3.8, n = 4 |
| A/Nebraska/1/2006 | A/H3N2 | S | R | 2.1 ± 1.3, n = 4 |
| A/Texas/12/2007 | A/H3N2 | R | R | 0.65 ± 0.22, n = 4 |
| A/California/07/2009 | A/H1N1pdm09 | S | R | 1.8 ± 1.6, n = 7 |
| A/Texas/48/2009 | A/H1N1pdm09 | R | R | 2.8 ± 3.2, n = 6 |
| A/Viet Nam/1203/2004 | A/H5N1 | S | R | <1.5, n = 1d |
a
R or S, neuraminidase inhibitor resistant or susceptible, respectively, as determined by enzymatic assay and publicly available sequences.
b
R or S, amantadine resistant (M2 31N mutation) or susceptible, respectively, as determined by analysis of publicly available sequences.
c
Data shown represent means ± standard deviations of the results of n independent experiments.
d
The experiment was performed at Southern Research Institute.